Is iCarbonX profitable in 2026?

iCarbonX discloses no audited financials as a private company, so profitability cannot be confirmed. It last raised a priced round in 2021 and still carries a 2016 vintage $1 billion unicorn valuation with no named pharma contracts reported as of 2025, making any profitability claim unverifiable.

Has iCarbonX raised new funding recently?

No confirmed funding round has been reported since a Series D of roughly $151 million by April 2021, per company-side historical reporting. Its $1 billion unicorn tag traces to a July 2016 Series A led by Tencent and Vcanbio, not a recent valuation event.

What does iCarbonX actually sell now?

Since 2019, iCarbonX says it pivoted from its original consumer 'digital life' genomics app to a B2B model, opening its multi-omics lab and data platform to pharma and biotech firms for biomarker discovery and drug development, though no named enterprise customers have surfaced as of 2025.

Who is iCarbonX's biggest competitor?

BGI, the Beijing Genomics Institute that founder Jun Wang once led as CEO, is iCarbonX's closest and most dangerous rival given its greater scale and data assets. Global players like Tempus and Guardant Health, plus new entrant BioAro's PanOmiQ multi-omics AI model launched October 2025, also compete directly.

Could AI replace iCarbonX's business?

iCarbonX's product is itself AI-driven multi-omics analysis, so it is not a target for outside AI disruption in the traditional sense. But BioAro announced a competing multi-omics foundation model, PanOmiQ, in October 2025, threatening to commoditize the AI-modeling layer iCarbonX relies on.

iCarbonX is privately held with no parent company; founder Dr. Jun Wang, former CEO of BGI, remains CEO. Early backers from its 2016 unicorn round included Tencent Holdings and Vcanbio, but no ownership change, IPO, or acquisition has been reported since then.

China · China

iCarbonX

Chinese multi-omics startup, once a $1B unicorn, now pivoting to pharma AI services.

Little protection left

Assessed 29 July 2026 · Evidence as of 29 July 2026

Not much stands between this business and its pressures.

On the recordSince 29 July 2026 · Checkable from 2026 · Every call on the record Checkpoint: Whether a fresh priced funding round or a named pharma contract surfaces

The call

iCarbonX still wears a 2016 unicorn label, but shows no confirmed funding since 2021, no named pharma customers, and new AI rivals moving into its own multi-omics niche.

iCarbonX says it can speed up drug discovery by analyzing many types of biological data (genes, proteins, metabolites) with artificial intelligence. The company abandoned its original plan to sell to consumers and is now trying to sell to pharmaceutical companies, but has not publicly named any customers or released independent proof that the approach works better than existing methods. Competitors like BGI (a much larger Chinese genomics company with the same founder) and newer AI startups like BioAro are building similar tools, so iCarbonX has no clear advantage; the critical test will be whether the company announces real partnerships with drug makers in the next six months and proves its silicon chip and million-person study are actually being used by paying customers, not just described in academic talks.

Why

AI pressure: BioAro/PanOmiQ multi-omics foundation model. A new foundation model for multi-omics data threatens to commoditize the exact AI-modeling layer iCarbonX is betting its pivot on. Could AI do the core job? Only partly.

Bigger players: BGI. BGI, the genomics giant iCarbonX's founder left, already runs multi-omics work at far greater scale and data volume. Could a giant copy it? Yes, easily.

What protects it. Founder Jun Wang's genomics reputation and early lab infrastructure, but no disclosed contract, data license, or chip deal locks anyone in.

What would change this call

A fresh priced funding round closes for iCarbonX in 2026. Would show investor confidence and set a current, real valuation.
iCarbonX names two or three multinational pharma clients with disclosed contract values. Would confirm the 2019 B2B pivot is generating real revenue.
The May 2025 silicon multi-omics chip and million-person pilot reach confirmed commercial deployment. Would prove the technology has moved from lab claim to shipped product.

Key numbers

$1B valuation reached (April 2016)
$154M-$155M Series A led by Tencent, Vcanbio (2016)
No confirmed new funding round (since 2021)

Named risks

No confirmed funding round since 2021 despite a stale 2016 unicorn valuation. Severity: high
No named pharma or biotech customers disclosed since 2019 B2B pivot. Severity: high
Foundation-model entrants like BioAro's PanOmiQ threaten to commoditize its AI layer. Severity: medium
Inconsistent headcount and revenue reporting suggests limited independent verification. Severity: medium
Chinese biotech data and cross-border data-flow regulation could restrict expansion. Severity: low

Rivals, as read in July 2026

Rival	Direction	Evidence
BGI	losing to	Founder's former employer retains far greater genomics scale and data as of 2025
Tempus	losing to	Public rival reported over $1.1 billion total contract value by Jan 2026
BioAro (PanOmiQ)	gaining on	Launched competing multi-omics foundation model Oct 2025, commoditizing AI layer
Guardant Health	contesting	Named category peer in precision-medicine genomics space per 2025 comparisons

Questions people ask

Is iCarbonX profitable in 2026?: iCarbonX discloses no audited financials as a private company, so profitability cannot be confirmed. It last raised a priced round in 2021 and still carries a 2016 vintage $1 billion unicorn valuation with no named pharma contracts reported as of 2025, making any profitability claim unverifiable.
Has iCarbonX raised new funding recently?: No confirmed funding round has been reported since a Series D of roughly $151 million by April 2021, per company-side historical reporting. Its $1 billion unicorn tag traces to a July 2016 Series A led by Tencent and Vcanbio, not a recent valuation event.
What does iCarbonX actually sell now?: Since 2019, iCarbonX says it pivoted from its original consumer 'digital life' genomics app to a B2B model, opening its multi-omics lab and data platform to pharma and biotech firms for biomarker discovery and drug development, though no named enterprise customers have surfaced as of 2025.
Who is iCarbonX's biggest competitor?: BGI, the Beijing Genomics Institute that founder Jun Wang once led as CEO, is iCarbonX's closest and most dangerous rival given its greater scale and data assets. Global players like Tempus and Guardant Health, plus new entrant BioAro's PanOmiQ multi-omics AI model launched October 2025, also compete directly.
Could AI replace iCarbonX's business?: iCarbonX's product is itself AI-driven multi-omics analysis, so it is not a target for outside AI disruption in the traditional sense. But BioAro announced a competing multi-omics foundation model, PanOmiQ, in October 2025, threatening to commoditize the AI-modeling layer iCarbonX relies on.
Who owns iCarbonX?: iCarbonX is privately held with no parent company; founder Dr. Jun Wang, former CEO of BGI, remains CEO. Early backers from its 2016 unicorn round included Tencent Holdings and Vcanbio, but no ownership change, IPO, or acquisition has been reported since then.

Timeline

2025-12-10Jun Wang details silicon multi-omics chip and AI modeling in Macau University lecture
2025-10-27Rival BioAro announces PanOmiQ, billed as world's first multi-omics LLM
2025-08-17CEO interview describes four diagnostic pipelines and 'health avatar' plans
2025-05iCarbonX announces silicon-based multi-omics chip targeting RMB 100 test cost
2021-04Company-reported Series D of about $151 million, last disclosed funding round
2019iCarbonX pivots from consumer platform to B2B multi-omics lab for pharma
2016-04Reaches $1 billion unicorn valuation after Series A led by Tencent and Vcanbio
2015-10-27iCarbonX founded by Dr. Jun Wang, former CEO of BGI

Revision history

29 July 2026

First assessed. Little protection left. The text above is fixed as of this date and is not edited afterwards.

In the same band

JOLLY Information Technology DeepBlue Technology 56PINGTAI